Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
1.170
-0.120 (-9.30%)
At close: Apr 10, 2026, 4:00 PM EDT
1.160
-0.010 (-0.85%)
After-hours: Apr 10, 2026, 7:27 PM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
92
Market Cap
152.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Agenus | 114.20M |
| Spero Therapeutics | 66.80M |
| Precision BioSciences | 34.26M |
| Whitehawk Therapeutics | 7.15M |
| Cartesian Therapeutics | 2.80M |
| Molecular Partners AG | 856.30K |
| Artiva Biotherapeutics | 251.00K |
IMUX News
- 2 days ago - Immunic to Participate in Scientific and Medical Conferences in April - PRNewsWire
- 10 days ago - Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 11 days ago - Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton - PRNewsWire
- 4 weeks ago - Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium - PRNewsWire
- 5 weeks ago - Immunic to Participate in Investor Conferences in March - PRNewsWire
- 6 weeks ago - Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - Immunic Announces Closing of Oversubscribed Private Placement Financing - PRNewsWire
- 2 months ago - Immunic Stock Jumps After Pricing $400 Million Private Placement - Benzinga